MBX Biosciences, Inc.
MBX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for endocrine and metabolic disorders, with lead candidates in hypoparathyroidism and obesity.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.03B
Cash Runway
53.5 moLead Asset
canvuparatide (Phase 3)Next Catalyst
Phase3_Topline · Aug 1, 2029Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials · 1 catalyst for MBX Biosciences, Inc..
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for endocrine and metabolic disorders, with lead candidates in hypoparathyroidism and obesity.
- Lead product candidate canvuparatide is being developed for hypoparathyroidism; the company reported preliminary Phase 2a STEADI trial results [sec_mda · as of 2026-08-06].
- Cash and equivalents of $54.1M as of 2026-06-30 [sec]; shareholders' equity of $369.2M as of the same date [sec].
- Accumulated deficit of $285.1M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Net loss of $37.1M for the quarter ended June 30, 2026 [sec].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-06].
What works
- The company has a pipeline of novel peptide-based candidates for endocrine and metabolic disorders, including canvuparatide, MBX 4291, MBX 5765, and MBX 6180 [sec_mda · as of 2026-08-06].
- MBX completed an initial public offering in September 2024, providing capital to advance its programs [sec_mda · as of 2026-08-06].
- The company's platform is designed to optimize pharmacokinetic and/or pharmacologic properties of peptide drugs [sec_mda · as of 2026-03-12].
What to weigh
- The company has an accumulated deficit of $285.1M as of June 30, 2026, and expects operating losses to increase substantially [sec_mda · as of 2026-08-06].
- MBX has no approved products and has never generated revenue from product sales; it will need substantial additional funding to support operations [sec_mda · as of 2026-08-06].
- The company decided not to advance imapextide into Phase 2b after preliminary Phase 2a results, indicating a setback in its obesity pipeline [sec_mda · as of 2026-08-06].
- Cash and equivalents of $54.1M as of June 30, 2026, may be limited relative to the company's ongoing clinical and operational expenses [sec].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $285.1 million as of June 30, 2026.
“We had an accumulated deficit of $285.1 million and $224.5 million as of June 30, 2026 and December 31, 2025, respectively.”
SEC MD&A · August 6, 2026
MBX decided not to proceed with a Phase 2b trial for imapextide after preliminary Phase 2a results.
“preliminary results from our Phase 2a STEADI™ trial. Given our growing number of novel peptide-based drug candidates and our expanding obesity pipeline, we will not be committing further investment toward a Phase 2b clinical trial of imapextide.”
SEC MD&A · August 6, 2026
The company has no approved products and has not generated any revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 6, 2026
MBX expects to need substantial additional funding to support its operations.
“As a result, we will need substantial additional funding to supp”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2029-08-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label — Topline data from the Phase 3 trial of canvuparatide for hypoparathyroidism will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has never generated product revenue; it depends on future regulatory approvals [sec_mda · as of 2026-08-06].
- Significant accumulated deficit — Accumulated deficit of $285.1M as of June 30, 2026, with expectations of increasing operating losses [sec_mda · as of 2026-08-06].
- Limited cash runway — Cash and equivalents of $54.1M as of June 30, 2026, may not be sufficient to fund all planned development activities [sec].
- Clinical development setbacks — Decision to discontinue imapextide Phase 2b after preliminary Phase 2a results highlights clinical risk [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline results for canvuparatide expected around August 1, 2029 [catalyst].
- Progress of other pipeline candidates MBX 4291, MBX 5765, and MBX 6180 through preclinical and clinical stages [sec_mda · as of 2026-08-06].
- Future financing events or partnerships to extend cash runway beyond current $54.1M [sec].
- Regulatory updates or trial initiations for the obesity pipeline following the imapextide discontinuation [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run MBX Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MBX Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
53.5 months
D/E 0.06 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~1067d
1 buy · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$1.32B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 3,637,887 | $108.6M |
| wellington management group llp | 3,191,824 | $95.3M |
| vanguard capital management llc | 2,955,184 | $88.2M |
| blackrock, inc. | 2,941,406 | $87.8M |
| fmr llc | 2,936,684 | $87.7M |
| deep track capital, lp | 2,757,569 | $82.3M |
| nvp associates, llc | 2,136,335 | $63.8M |
| woodline partners lp | 1,800,126 | $53.7M |
| polar capital holdings plc | 1,622,186 | $48.4M |
| braidwell lp | 1,492,467 | $44.6M |
Showing top 10 of 156 institutional holders of MBX Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 11.2%
- Days to cover
- 8.0
- Shares short
- 3,786,542
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MBX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MBX Biosciences, Inc.?
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for endocrine and metabolic disorders, with lead candidates in hypoparathyroidism and obesity.
What is MBX Biosciences, Inc.'s lead drug candidate?
MBX Biosciences, Inc.'s most advanced tracked candidate is canvuparatide (Phase 3) for Hypoparathyroidism.
What is MBX Biosciences, Inc.'s next catalyst?
MBX Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label" — expected August 1, 2029.
Who is the CEO of MBX Biosciences, Inc.?
Mr. Steven L. Hoerter is the chief executive officer of MBX Biosciences, Inc. (MBX).
Where is MBX Biosciences, Inc. headquartered?
MBX Biosciences, Inc. (MBX) is headquartered in Carmel, IN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.